ACTRT2

Across TCGA pan-cancer cohorts, ACTRT2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACTRT2 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ACTRT2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACTRT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, PRAD, and ESCA are the cancer types where ACTRT2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.085	0.684	<.001	24	view →
PRAD	DFS	Median	All	0.113	0.886	<.001	6	view →
ESCA	OS	Median	All	0.141	0.700	.003	6	view →
UCEC	OS	Median	II,III,IV	0.927	0.460	.030	4	view →
LUSC	DFS	Median	II,III,IV	0.179	0.712	.002	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACTRT2–BLCA (OS)

Open the BLCA breakdown →